Paper: The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma
In a 5 year follow up subgroup analysis of BV-CHP vs CHOP for PTCL, the AITL subgroup had no benefit of BV-CHP over CHOP, and in fact PFS favored CHOP. Recall, that this trial was specifically designed to be enriched for 75% ALCL which carried the treatment across subgroups. AITL remains an aggressive disease which requires more effective therapies.
